- Drugs
- Thursday, 19 Sep 2019
Aphria Inc Launches Plant Positivity Social Impact Platform with Evergreen
Aphria Inc. announced the launch of its new social impact platform, Plant Positivity. The company partnered with not-for-profit Evergreen which will create six new garden spaces at Evergreen Brick Works.
Aphria, Inc. is engaged in the production and supply of medical cannabis. It operates through three reportable segments including cannabis operations, distribution operations, and business under development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada. Aphria’s subsidiaries include Pure Natures Wellness Inc. that are engaged in the production and distribution of medical marijuana, and Cannway Pharmaceuticals Ltd., which specializes in offering support services to veterans and their first responders.
Related Industry Updates
CaaMTech Collaborates With National Institutes of Health to Research Psychedelics
May 08, 2020
North America Radiopharmaceutical Theragnostic Market is expected to reach US$ 1,529.88 million by 2028
Mar 13, 2023
Empty Capsules Market is?expected reach US$ 12.52 billion by 2030
Feb 01, 2024
Starch Softgel Capsules Market Breakdown, Development and New Market Opportunities & Forecasts 2027
Jul 21, 2020
ACG Inspection Introduces Groundbreaking Blockchain-based Brand Platform
Feb 07, 2020
US Pharmacy Management System Market is expected to reach US$ 53,139.59 million by 2030
Sep 21, 2023
Idiopathic Pulmonary Fibrosis Treatment Market is expected to reach US$ 10,784.07 million by 2030
Dec 12, 2023